Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
IMV (GB:0V11)
LSE:0V11
IMV (0V11) Share Price & Analysis
0 Followers
0V11 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
IMV News
0V11 FAQ
What was IMV’s price range in the past 12 months?
Currently, no data Available
What is IMV’s market cap?
Currently, no data Available
When is IMV’s upcoming earnings report date?
IMV’s upcoming earnings report date is Mar 14, 2024 which is 43 days ago.
How were IMV’s earnings last quarter?
Currently, no data Available
Is IMV overvalued?
According to Wall Street analysts IMV’s price is currently same.
Does IMV pay dividends?
IMV does not currently pay dividends.
What is IMV’s EPS estimate?
IMV’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IMV have?
IMV has 11,711,637 shares outstanding.
What happened to IMV’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IMV?
Currently, no hedge funds are holding shares in GB:0V11
---
Company Description
IMV
IMV, Inc. is a clinical-stage biopharmaceutical company pioneering a new class of immunotherapy in Oncology. Its proprietary drug delivery platform (DPX) enables the programming of immune cells in vivo. The firm's candidate, DPX-Survivac, is a T cell-activating immunotherapy combining DPX with a specific tumor target: Survivin. DPX-Survivac is in clinical evaluation as a monotherapy in advanced ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. The company was founded by Warwick Kimmins and Brian E. Lowe on March 28, 2000 and is headquartered in Dartmouth, Canada.
---
0V11 Company Deck
---
0V11 Earnings Call
Q4 2023
0:00 / 0:00
---
0V11 Stock 12 Months Forecast
Average Price Target
―---